Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

969 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety, tolerability, pharmacokinetic, pharmacodynamic and immunogenicity profiles of Exendin-4-IgG4-Fc in healthy subjects: A phase 1, single-centre, randomized, double-blind, dose escalation study.
Chen GL, Liu Y, Gao XF, Wu KQ, Yang YK, Chen Y, Peng CG, Jin TH, Huang YB, Zhang YW, Su J, Jiang Q, Guo T, Zhao J, Peng XN, Peng JY, Li SX, Sun YL, Zhang HM, Fu YL, Luo D, Ma Y, Shen ZW, Zhang YT, Shou ZF. Chen GL, et al. Among authors: zhang hm, zhang yt, zhang yw. Diabetes Obes Metab. 2024 Apr;26(4):1395-1406. doi: 10.1111/dom.15441. Epub 2024 Jan 29. Diabetes Obes Metab. 2024. PMID: 38287130 Clinical Trial.
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial.
Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, Tan W, Wu G, Xu M, Lou Z, Huang W, Xu W, Huang B, Wang H, Wang W, Zhang W, Li N, Xie Z, Ding L, You W, Zhao Y, Yang X, Liu Y, Wang Q, Huang L, Yang Y, Xu G, Luo B, Wang W, Liu P, Guo W, Yang X. Xia S, et al. Lancet Infect Dis. 2021 Jan;21(1):39-51. doi: 10.1016/S1473-3099(20)30831-8. Epub 2020 Oct 15. Lancet Infect Dis. 2021. PMID: 33069281 Free PMC article. Clinical Trial.
Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial.
Al Kaabi N, Zhang Y, Xia S, Yang Y, Al Qahtani MM, Abdulrazzaq N, Al Nusair M, Hassany M, Jawad JS, Abdalla J, Hussein SE, Al Mazrouei SK, Al Karam M, Li X, Yang X, Wang W, Lai B, Chen W, Huang S, Wang Q, Yang T, Liu Y, Ma R, Hussain ZM, Khan T, Saifuddin Fasihuddin M, You W, Xie Z, Zhao Y, Jiang Z, Zhao G, Zhang Y, Mahmoud S, ElTantawy I, Xiao P, Koshy A, Zaher WA, Wang H, Duan K, Pan A, Yang X. Al Kaabi N, et al. JAMA. 2021 Jul 6;326(1):35-45. doi: 10.1001/jama.2021.8565. JAMA. 2021. PMID: 34037666 Free PMC article. Clinical Trial.
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18 years or older: A randomized, double-blind, placebo-controlled, phase 1/2 trial.
Guo W, Duan K, Zhang Y, Yuan Z, Zhang YB, Wang Z, Zhao D, Zhang H, Xie Z, Li X, Peng C, Zhang W, Yang Y, Chen W, Gao X, You W, Wang XW, Shi Z, Wang Y, Yang XQ, Zhang L, Huang L, Wang Q, Lu J, Yang YL, Guo J, Zhou W, Wan X, Wu C, Wang W, Du J, Nian X, Li XH, Huang S, Shen S, Xia S, Pan A, Yang X. Guo W, et al. EClinicalMedicine. 2021 Aug;38:101010. doi: 10.1016/j.eclinm.2021.101010. Epub 2021 Jul 7. EClinicalMedicine. 2021. PMID: 34250456 Free PMC article.
Safety and Immunogenicity of an Inactivated COVID-19 Vaccine, WIBP-CorV, in Healthy Children: Interim Analysis of a Randomized, Double-Blind, Controlled, Phase 1/2 Trial.
Xia S, Duan K, Zhang Y, Zeng X, Zhao D, Zhang H, Xie Z, Li X, Peng C, Zhang W, Yang Y, Chen W, Gao X, You W, Wang X, Wang Z, Shi Z, Wang Y, Yang X, Li Q, Huang L, Wang Q, Lu J, Yang Y, Guo J, Zhou W, Wan X, Wu C, Wang W, Huang S, Du J, Nian X, Deng T, Yuan Z, Shen S, Guo W, Liu J, Yang X. Xia S, et al. Front Immunol. 2022 Jun 24;13:898151. doi: 10.3389/fimmu.2022.898151. eCollection 2022. Front Immunol. 2022. PMID: 35812412 Free PMC article. Clinical Trial.
Efficacy and Safety of a Booster Vaccination with Two Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: Results of a Double-Blind, Randomized, Placebo-Controlled, Phase 3 Trial in Abu Dhabi.
Al Kaabi N, Yang Y, Eldin Hussein S, Yang T, Abdalla J, Wang H, Lou Z, Chinese Center For Disease Control And Prevention, Bakkour A, Arafat A, China National Biotec Group Company Limited, Jiang Z, Tian Y, National Engineering Technology Research Center For Combined Vaccines Wuhan Institute Of Biological Products Co Ltd, Beijing Institute Of Biological Products Company Limited, Xiao P, Zaher W, Eltantawy I, Wang C, Xu G, Zhang Y, Yang X. Al Kaabi N, et al. Vaccines (Basel). 2023 Jan 30;11(2):299. doi: 10.3390/vaccines11020299. Vaccines (Basel). 2023. PMID: 36851177 Free PMC article.
Outcome benefits of bevacizumab biosimilar (SIBP04) combined with carboplatin and paclitaxel in advanced non-squamous non-small-cell lung cancer patients with EGFR mutation: subgroup analysis of a prospective, randomized phase III clinical trial.
Qu A, Zhang S, Zou H, Li S, Chen D, Zhang Y, Li S, Zhang H, Yang J, Yang Y, Huang Y, Li X, Zhang Y. Qu A, et al. J Cancer Res Clin Oncol. 2023 Nov;149(14):12713-12721. doi: 10.1007/s00432-023-05103-4. Epub 2023 Jul 15. J Cancer Res Clin Oncol. 2023. PMID: 37452849
Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials.
Xia S, Duan K, Zhang Y, Zhao D, Zhang H, Xie Z, Li X, Peng C, Zhang Y, Zhang W, Yang Y, Chen W, Gao X, You W, Wang X, Wang Z, Shi Z, Wang Y, Yang X, Zhang L, Huang L, Wang Q, Lu J, Yang Y, Guo J, Zhou W, Wan X, Wu C, Wang W, Huang S, Du J, Meng Z, Pan A, Yuan Z, Shen S, Guo W, Yang X. Xia S, et al. JAMA. 2020 Sep 8;324(10):951-960. doi: 10.1001/jama.2020.15543. JAMA. 2020. PMID: 32789505 Free PMC article. Clinical Trial.
969 results